IP Group was among the investors for UPenn-founded cancer immunotherapy developer Carisma Therapeutics, which has now raised nearly $109m altogether.

Carisma Therapeutics, a US-based cancer immunotherapy spinout of University of Pennsylvania, closed a $47m series B round on Thursday featuring commercialisation firm IP Group. The round was led by investment fund Symbiosis II and also included drug development firms Livzon Pharmaceutical, Merck & Co and AbbVie, the latter two participating through MRL Ventures Fund and…

The rest of this content is only accessible to University Venturing: News, Data, and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.